1. Kinetics of rhodopsin deactivation and its role in regulating recovery and reproducibility of rod photoresponse. Caruso G, Bisegna P, Lenoci L, Andreucci D, Gurevich VV, Hamm HE, DiBenedetto E (2010) PLoS Comput Biol 6(12): e1001031
    › Primary publication · 21200415 (PubMed) · PMC3002991 (PubMed Central)
  2. Elucidation of inositol hexaphosphate and heparin interaction sites and conformational changes in arrestin-1 by solution nuclear magnetic resonance. Zhuang T, Vishnivetskiy SA, Gurevich VV, Sanders CR (2010) Biochemistry 49(49): 10473-85
    › Primary publication · 21050017 (PubMed) · PMC3074303 (PubMed Central)
  3. Dynamics of mouse rod phototransduction and its sensitivity to variation of key parameters. Shen L, Caruso G, Bisegna P, Andreucci D, Gurevich VV, Hamm HE, DiBenedetto E (2010) IET Syst Biol 4(1): 12-32
    › Primary publication · 20001089 (PubMed) · PMC3833298 (PubMed Central)
  4. Custom-designed proteins as novel therapeutic tools? The case of arrestins. Gurevich VV, Gurevich EV (2010) Expert Rev Mol Med : e13
    › Primary publication · 20412604 (PubMed) · PMC2933791 (PubMed Central)
  5. Overexpression of rhodopsin alters the structure and photoresponse of rod photoreceptors. Wen XH, Shen L, Brush RS, Michaud N, Al-Ubaidi MR, Gurevich VV, Hamm HE, Lem J, Dibenedetto E, Anderson RE, Makino CL (2009) Biophys J 96(3): 939-50
    › Primary publication · 19186132 (PubMed) · PMC2716671 (PubMed Central)
  6. How does arrestin assemble MAPKs into a signaling complex? Song X, Coffa S, Fu H, Gurevich VV (2009) J Biol Chem 284(1): 685-95
    › Primary publication · 19001375 (PubMed) · PMC2610502 (PubMed Central)
  7. Enhanced arrestin facilitates recovery and protects rods lacking rhodopsin phosphorylation. Song X, Vishnivetskiy SA, Gross OP, Emelianoff K, Mendez A, Chen J, Gurevich EV, Burns ME, Gurevich VV (2009) Curr Biol 19(8): 700-5
    › Primary publication · 19361994 (PubMed) · PMC2768495 (PubMed Central)
  8. An intracellular loop 2 amino acid residue determines differential binding of arrestin to the dopamine D2 and D3 receptors. Lan H, Teeter MM, Gurevich VV, Neve KA (2009) Mol Pharmacol 75(1): 19-26
    › Primary publication · 18820126 (PubMed) · PMC2606909 (PubMed Central)
  9. Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. Dinieri JA, Nemeth CL, Parsegian A, Carle T, Gurevich VV, Gurevich E, Neve RL, Nestler EJ, Carlezon WA (2009) J Neurosci 29(6): 1855-9
    › Primary publication · 19211892 (PubMed) · PMC2666984 (PubMed Central)
  10. A dopamine D2 receptor mutant capable of G protein-mediated signaling but deficient in arrestin binding. Lan H, Liu Y, Bell MI, Gurevich VV, Neve KA (2009) Mol Pharmacol 75(1): 113-23
    › Primary publication · 18809670 (PubMed) · PMC2606918 (PubMed Central)